Literature DB >> 31784280

High plasma microfibrillar-associated protein 4 is associated with reduced surgical repair in abdominal aortic aneurysms.

Jes Sanddal Lindholt1, Mathilde Madsen2, Katrine Lindequist Kirketerp-Møller2, Anders Schlosser2, Katrine Lawaetz Kristensen3, Carsten Behr Andersen1, Grith Lykke Sorensen4.   

Abstract

OBJECTIVE: Identifying biomarkers for abdominal aortic aneurysms (AAA) could prove beneficial in prognosis of AAA and thus the selection for treatment. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein that is highly expressed in aorta. MFAP4 is involved in several tissue remodeling-related diseases. We aimed to investigate the potential role of plasma MFAP4 (pMFAP4) as a biomarker of AAA.
METHODS: Plasma samples and data were obtained for 504 male AAA patients and 188 controls in the Viborg Vascular (VIVA) screening trial. The pMFAP4 levels were measured by Alphalisa. The Mann-Whitney U test assessed differences in pMFAP4 levels between the presence and absence of different exposures of interest. The correlation between pMFAP4 and aorta growth rate were investigated through spearman's correlation analysis. Immunohistochemistry and multiple logistic regression adjusted for potential confounders assessed the association between pMFAP4 and AAA. Multiple linear regression assessed the correlation between pMFAP4 and aorta growth rate. Cox regression and competing risk regression were used to investigate the correlation between AAA patients with upper tertile pMFAP4 and the risk of undergoing later surgical repair.
RESULTS: A significant negative correlation between pMFAP4 and aorta growth rate was observed using spearman's correlation analysis (ρ = -0.14; P = .0074). However, this finding did not reach significance when applying multiple linear regression. A tendency of decreased pMFAP4 was observed in AAA using immunohistochemistry. Competing risk regression adjusted for potential confounders indicated that patients with upper tertile pMFAP4 had a hazard ratio of 0.51 (P = .001) for risk of undergoing later surgical repair.
CONCLUSIONS: High levels of pMFAP4 are associated with a decreased likelihood of receiving surgical repair in AAA. This observation warrants confirmation in an independent cohort.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abdominal aorta aneurysms; Extracellular matrix; Growth rate; MFAP4; Surgical repair

Mesh:

Substances:

Year:  2019        PMID: 31784280     DOI: 10.1016/j.jvs.2019.08.253

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Development and Validation of a Prognostic Nomogram Based on DNA Methylation-Driven Genes for Patients With Ovarian Cancer.

Authors:  Min Zhou; Shasha Hong; Bingshu Li; Cheng Liu; Ming Hu; Jie Min; Jianming Tang; Li Hong
Journal:  Front Genet       Date:  2021-09-09       Impact factor: 4.772

2.  Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4.

Authors:  Susanne Gjørup Sækmose; René Holst; Tine Lottenburger; Henriette Ytting; Hans Jørgen Nielsen; Peter Junker; Anders Schlosser; Grith Lykke Sorensen
Journal:  Biomark Insights       Date:  2021-05-14

3.  Identification of crucial genes involved in pathogenesis of regional weakening of the aortic wall.

Authors:  Hong Lin Zu; Hong Wei Liu; Hai Yang Wang
Journal:  Hereditas       Date:  2021-12-02       Impact factor: 3.271

4.  Exploration of the Important Role of Microfibril-Associated Protein 4 Gene in Oral Squamous Cell Carcinoma.

Authors:  Ying Han; Kun Xia; Tong Su
Journal:  Med Sci Monit       Date:  2021-07-02

5.  IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features.

Authors:  Javier Rodríguez-Carrio; Jes S Lindholt; Marina Canyelles; Diego Martínez-López; Mireia Tondo; Luis M Blanco-Colio; Jean-Baptiste Michel; Joan Carles Escolà-Gil; Ana Suárez; José Luis Martín-Ventura
Journal:  J Clin Med       Date:  2019-12-26       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.